Anavex Presents Neuroprotective Effects Of Anavex 1-41 At The International Conference On Alzheimer's Disease 2008 ANAVEX Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, presented data from the company's novel compound, ANAVEX 1-41, targeting Alzheimer's disease, at the International Conference on Alzheimer's Disease (ICAD) 2008, Chicago, USA, July 26 to 31, 2008.
Source: www.medicalnewstoday.comMemory Pharmaceuticals Presents Positive Preclinical Data For MEM 68626 At ICAD 2008 Memory Pharmaceuticals Corp. (Nasdaq: MEMY) presented preclinical data for MEM 68626, its lead 5-HT6 antagonist drug candidate, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago. The results demonstrate that MEM 68626 is effective in models of cognition that are considered predictive of efficacy in Alzheimer's disease and mild cognitive impairment (MCI).
Source: www.medicalnewstoday.comGSK - Changes To Medicines Distribution Arrangements, UK GSK UK has announced that from 1st November 2008 it will partner with two of its current logistics service providers, AAH Pharmaceuticals Ltd and UniChem Ltd, to deliver its
prescription medicines to customers in the UK. The NPA's Board will discuss this development at its meeting today. NPA chief executive, John Turk, said: "The NPA board will discuss urgently the implications of this new development for our members.
Source: www.medicalnewstoday.comPotential HHS Rule Would Override Minn. Law Requiring Hospitals To Provide EC, Advocates Say On Tuesday, Minnesota legislators and women's
health advocates warned that a proposed regulation being developed by the Bush administration -- a regulation that allegedly seeks t
Source: www.medicalnewstoday.com
# posted by Network @ 7:00 PM
